Patents by Inventor Christopher M. Clemens

Christopher M. Clemens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160282353
    Abstract: Provided is an assay system and method that includes binding a conjugate to a target receptor on a surface of malignant blood cells included in the liquid medium to form labeled malignant blood cells. The liquid medium including the labeled malignant blood cells is exposed to a magnetic field to separate the labeled malignant blood cells from unlabeled blood cells in the liquid medium. In the presence of the magnet field, at least a portion of the liquid medium is removed to isolate the labeled malignant blood cells separated by the magnetic field. A sample comprising at least a portion of the labeled malignant blood cells separated by the magnetic field is then introduced into a flow cytometer to quantify the labeled malignant blood cells present in the sample.
    Type: Application
    Filed: March 28, 2016
    Publication date: September 29, 2016
    Inventors: Christopher M. Clemens, Joseph R. Firca
  • Publication number: 20040062771
    Abstract: Treating humans and animals intoxicated with a bacterial toxin by administration of antitoxin. Avian antitoxin in an aqueous solution in therapeutic amount that is orally administrable.
    Type: Application
    Filed: September 15, 2003
    Publication date: April 1, 2004
    Applicant: PROMEGA Corporation
    Inventors: Sean B. Carroll, Margaret B. van Boldrik, Christopher M. Clemens
  • Patent number: 6693083
    Abstract: A composition for intracellular delivery of a chemical agent into an interleukin-2-receptor-bearing cell, e.g. an activated T cell, includes a chemical agent and at least one copy of an interleukin-2-receptor-binding and endocytosis-inducing ligand coupled to a water soluble polymer. The ligand binds to a receptor on the interleukin-2-receptor-bearing cell and elicits endocytosis of the composition. The composition also preferably includes a spacer for coupling the chemical agent and the ligand to the polymer. Chemical agents can include cytotoxins, transforming nucleic acids, gene regulators, labels, antigens, drugs, and the like. A preferred water soluble polymer is a polyalkylene oxide, such as polyethlene glycol and polyethylene oxide, and activated derivatives thereof. The composition can further comprise a carrier such as another water soluble polymer, liposome, or particulate. Methods of using these compositions for delivering a chemical agent in vivo or in vitro are also disclosed.
    Type: Grant
    Filed: February 12, 2001
    Date of Patent: February 17, 2004
    Assignee: Watson Pharmaceuticals, Inc.
    Inventors: Ramesh K. Prakash, Christopher M. Clemens
  • Patent number: 6656468
    Abstract: Treating humans and animals intoxicated with a bacterial toxin by administration of antitoxin. Avian antitoxin in an aqueous solution in therapeutic amount that is orally administrable.
    Type: Grant
    Filed: March 5, 1997
    Date of Patent: December 2, 2003
    Assignee: Promega Corporation
    Inventors: Sean B. Carroll, Margaret B. van Boldrik, Christopher M. Clemens
  • Publication number: 20030012785
    Abstract: A composition for intracellular delivery of a chemical agent into an interleukin-2-receptor-bearing cell, e.g. an activated T cell, includes a chemical agent and at least one copy of an interleukin-2-receptor-binding and endocytosis-inducing ligand coupled to a water soluble polymer. The ligand binds to a receptor on the interleukin-2-receptor-bearing cell and elicits endocytosis of the composition. The composition also preferably includes a spacer for coupling the chemical agent and the ligand to the polymer. Chemical agents can include cytotoxins, transforming nucleic acids, gene regulators, labels, antigens, drugs, and the like. A preferred water soluble polymer is a polyalkylene oxide, such as polyethlene glycol and polyethylene oxide, and activated derivatives thereof. The composition can further comprise a carrier such as another water soluble polymer, liposome, or particulate. Methods of using these compositions for delivering a chemical agent in vivo or in vitro are also disclosed.
    Type: Application
    Filed: February 12, 2001
    Publication date: January 16, 2003
    Inventors: Ramesh K. Prakash, Christopher M. Clemens
  • Patent number: 6251866
    Abstract: A composition for intracellular delivery of a chemical agent into an interleukin-2-receptor-bearing cell, e.g. an activated T cell, includes a chemical agent and at least one copy of an interleukin-2-receptor-binding and endocytosis-inducing ligand coupled to a water soluble polymer. The ligand binds to a receptor on the interleukin-2-receptor-bearing cell and elicits endocytosis of the composition. The composition also preferably includes a spacer for coupling the chemical agent and the ligand to the polymer. Chemical agents can include cytotoxins, transforming nucleic acids, gene regulators, labels, antigens, drugs, and the like. A preferred water soluble polymer is a polyalkylene oxide, such as polyethlene glycol and polyethylene oxide, and activated derivatives thereof. The composition can further comprise a carrier such as another water soluble polymer, liposome, or particulate. Methods of using these compositions for delivering a chemical agent in vivo or in vitro are also disclosed.
    Type: Grant
    Filed: August 4, 1998
    Date of Patent: June 26, 2001
    Assignee: Watson Laboratories, Inc.
    Inventors: Ramesh K. Prakash, Christopher M. Clemens
  • Patent number: 5814477
    Abstract: The present invention includes methods for the production and purification of recombinant clostridial toxin proteins.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: September 29, 1998
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventors: James A. Williams, John A. Kink, Christopher M. Clemens, Sean B. Carroll
  • Patent number: 5762934
    Abstract: The present invention includes methods and compositions for treating humans and other animals intoxicated with at least one clostridial toxin by administration of antitoxin. In particular, the antitoxin directed against these toxins is produced in avian species. This avian antitoxin is designed so as to be orally administerable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution).
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: June 9, 1998
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventors: James A. Williams, John A. Kink, Christopher M. Clemens, Sean B. Carroll
  • Patent number: 5719267
    Abstract: Treating humans and animals intoxicated with a bacterial toxin by administration of antitoxin. Avian antitoxin in an aqueous solution in therapeutic amount that is orally administrable.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: February 17, 1998
    Assignee: Ophidian Pharmaceuticals Inc.
    Inventors: Sean B. Carroll, Margaret B. van Boldrik, Christopher M. Clemens
  • Patent number: 5601823
    Abstract: The present invention includes methods and compositions for treating humans and other animals intoxicated with at least one Clostridial toxin by administration of antitoxin. In particular, the antitoxin directed against these toxins is produced in avian species. This avian antitoxin is designed so as to be orally administerable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution).
    Type: Grant
    Filed: December 2, 1993
    Date of Patent: February 11, 1997
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventors: James A. Williams, John A. Kink, Christopher M. Clemens, Sean B. Carroll
  • Patent number: 5599539
    Abstract: Treating humans and animals intoxicated with a bacterial toxin by administration of antitoxin. Avian antitoxin in an aqueous solution in therapeutic amount that is orally administrable.
    Type: Grant
    Filed: June 7, 1994
    Date of Patent: February 4, 1997
    Assignee: Ophidian Pharmaceuticals, Inc.
    Inventors: Sean B. Carroll, Margaret B. van Boldrik, Christopher M. Clemens